share_log

Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022

Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022

Sientra将于2022年8月11日公布2022年第二季度财务业绩
GlobeNewswire ·  2022/07/28 20:41

SANTA BARBARA, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) ("Sientra" or the "Company"), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the second quarter of 2022 after the close of trading on Thursday, August 11, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

圣巴巴拉,加利福尼亚州,2022年7月28日(环球社)--西恩特拉公司(纳斯达克代码:SEN)(以下简称“西恩特拉”或“公司”),一家专注于通过提升整形手术艺术来改善生活的医疗美容公司,今天宣布,它将在周二收盘后公布2022年第二季度的财务业绩。2022年8月11日星期四。Sientra将在同一天主持一次电话会议,讨论财务业绩下午4:30东部时间.

The dial-in numbers are 1-866-374-5140 for domestic callers. The conference ID is 32094933. The webcast link is the following: Sientra Q2' 2022 Earnings Call Webcast Registration Link.

国内来电的拨入号码是1-866-374-5140。会议ID为32094933。网络直播链接如下:Sientra Q2‘2022财报电话会议网络直播注册链接.

A live webcast of the conference call will be available on the Investor Relations section of the Company's website at . The webcast will be archived on the website following the completion of the call.

电话会议的现场网络直播将在该公司网站的投资者关系部分进行,网址为:。电话会议结束后,网络直播将在网站上存档。

About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company's product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).

关于Sientra
Sientra总部位于加利福尼亚州圣巴巴拉,是一家专注于整形手术的医学美学公司。该公司的使命是提供专有创新和无与伦比的合作伙伴关系,从根本上促进整形外科医生思考、工作和护理病人的方式。Sientra开发了广泛的产品组合,具有技术差异化的特点,并得到独立实验室测试和强大的临床试验结果的支持。该公司的产品组合包括Sientra圆形和成型乳房植入物、FDA批准在美国销售的第一批第五代乳房植入物、其突破性的Allx2®拥有专利的双端口和集成引流技术的乳房组织扩张器、AuraGen脂肪移植系统和BIOCORNEUM®,整形外科医生首选和推荐的头号疤痕凝胶(*)。

Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company's investor relations website at .

Sientra使用其投资者关系网站发布有关公司的重要信息,包括可能被认为对投资者具有重大意义的信息。有关Sientra的财务和其他信息会定期发布,并可在公司的投资者关系网站上访问。

(*) Data on file

(*)数据已备案

Investor Relations Contact
Aman R. Patel, CFA
aman.patel@westwicke.com

投资者关系联系人
Aman R.Patel,CFA
邮箱:aman.patel@westwicke.com


译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发